Provided by Tiger Trade Technology Pte. Ltd.

Pasithea Therapeutics Corp.

0.7970
+0.01491.91%
Post-market: 0.79700.00000.00%16:38 EDT
Volume:205.11K
Turnover:161.21K
Market Cap:18.40M
PE:-0.15
High:0.8117
Open:0.7650
Low:0.7576
Close:0.7821
52wk High:3.79
52wk Low:0.2810
Shares:23.09M
Float Shares:18.52M
Volume Ratio:2.54
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.2115
EPS(LYR):-12.6857
ROE:-89.90%
ROA:-53.70%
PB:1.51
PE(LYR):-0.06

Loading ...

Crude Oil Gains 1%; Tilray Brands Shares Plunge

Benzinga
·
Nov 29, 2025

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:32 AM

Reuters
·
Nov 28, 2025

Pasithea Therapeutics prices 80M shares at 75c in public offering

TIPRANKS
·
Nov 28, 2025

Pasithea Therapeutics Corp - Cash Position to Extend Runway Through First Half of 2028

THOMSON REUTERS
·
Nov 28, 2025

Pasithea Therapeutics Corp - Prices Public Offering of 80 Mln Shares at $0.75 Each

THOMSON REUTERS
·
Nov 28, 2025

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

GlobeNewswire
·
Nov 28, 2025

3 Penny Stocks to Watch Now, 11/27/25

TIPRANKS
·
Nov 27, 2025

Why Pasithea Therapeutics (KTTA) Stock Is Suddenly On Fire Today

Benzinga_recent_news
·
Nov 26, 2025

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:44 AM

Reuters
·
Nov 26, 2025

Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004

TIPRANKS
·
Nov 26, 2025

Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS

GlobeNewswire
·
Nov 25, 2025

Pasithea Therapeutics Unveils Investor Presentation Highlighting Next-Generation MEK Inhibitor PAS-004 for Cancer and NF1

Reuters
·
Nov 25, 2025

BRIEF-Pasithea Therapeutics Announces Completion Of Cohort 7 In Ongoing Phase 1 Trial Of Pas-004

Reuters
·
Nov 24, 2025

Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004

TIPRANKS
·
Nov 24, 2025

Pasithea Therapeutics Corp - Safety Review Committee Recommends Escalation to Cohort 8

THOMSON REUTERS
·
Nov 24, 2025

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of Pas-004 in Advanced Cancer Patients, With Positive Safety, Pharmacokinetic (Pk), and Pharmacodynamic (Pd) Data

THOMSON REUTERS
·
Nov 24, 2025

Pasithea Therapeutics Corp -Zero Treatment Related Adverse Events Observed During Cohort 7 (37Mg Capsules) Dlt Period

THOMSON REUTERS
·
Nov 24, 2025

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

GlobeNewswire
·
Nov 24, 2025

Pasithea Therapeutics Announces Positive Pas-004 Tablet Pharmacokinetic (Pk) Data in Ongoing Phase 1/1B Trial in Adult Nf1 Patients

THOMSON REUTERS
·
Nov 22, 2025

Pasithea Therapeutics Corp - Tablet Pk Exposure Increases Proportionally With Dose

THOMSON REUTERS
·
Nov 22, 2025